Johnson & Johnson (NYSE: JNJ) is a global healthcare company. It operates through two main divisions: Innovative Medicine, which develops new drugs, and MedTech, which provides medical devices and technology. The company competes with other major pharmaceutical and medical device firms worldwide, navigating challenges like biosimilar competition for its key drugs.
Analyst firm RBC Capital recently increased its price target on Johnson & Johnson to $265.00 from $255.00, maintaining an "Outperform" rating. This rating suggests the stock is expected to perform better than the overall market. At the time of the update, the stock was trading at $240.10 per share.
This positive outlook follows a strong first-quarter 2026 performance. The company reported worldwide sales of $24.1 billion, a 6.4% operational increase. Net earnings were $5.2 billion, which translates to $2.14 per diluted share. A diluted share count includes all possible shares, giving a more complete earnings picture.
Growth was strong across its business. The Innovative Medicine division's sales grew 7.4%, with drugs like Darzalex and Tremfya performing well. The MedTech segment also saw sales increase by 4.6%, led by its cardiovascular and surgery products. This growth helped offset a sales decline for its drug Stelara.
Based on these results, Johnson & Johnson raised its full-year 2026 operational sales growth forecast to a range of 5.9% to 6.9%. As highlighted by MarketBeat, some analysis suggests a potential 20% gain for the stock. The company has a market capitalization of approximately $578.62 billion, with a 52-week trading range between $146.12 and $251.71.
